Login to Your Account



No Working Kinase, but ErbB3 Acquires Oncogenic Mutations

By Anette Breindl
Science Editor

Tuesday, May 14, 2013
The ErbB family of receptor tyrosine kinases is well known to drug developers. ErbB1, or EGFR, is the target of drugs such as Tarceva (erlotinib, Roche AG and Astellas Pharma Inc.), Iressa (gefitinib, AstraZeneca plc.), Vectibix (panitumumab, Amgen Inc.) and Erbitux (cetuximab, Eli Lilly and Co.) Roche drugs Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) target ErbB2, which also goes by HER2/neu.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription